11Apr 2023
Monitoring Minimal Residual Disease Using KMT2A Genomic Breakpoint Sequences in Acute Leukemia Patients

Monitoring Minimal Residual Disease Using KMT2A Genomic Breakpoint Sequences in Acute Leukemia Patients

This study analyzed data from 3401 acute leukemia patients between 2003 and 2022 to determine genomic breakpoints within the KMT2A gene and involved translocation partner genes. 107 in-frame KMT2A gene fusions were identified, along with 16 out-of-frame fusions, 18 patients with no partner gene fused to 5’-KMT2A, two patients with a 5’-KMT2A deletion, and one patient with a KMT2A insertion at the breakpoint. The study provides a comprehensive analysis of the KMT2A recombinome in acute leukemia patients, and the genomic breakpoint sequences can be used to monitor minimal residual disease (MRD) and improve patient survival.

  • #oncology

Like

Save

Share